Uncategorized

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Zylox-Tonbridge, a leading medical device company in the peripheral and neurovascular interventional market in China, announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease.

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions Read More »

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Innovent Biologics, Inc. announced that the results of two clinical studies of IBI311,a Phase I trial in healthy subjects and a Phase II trial in patients with thyroid eye disease, in the form of oral presentation at the 39th Asia Pacific Academy of Ophthalmology Congress and the 21st International Congress of Endocrinology, respectively.

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Read More »

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Inc. announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants Read More »

Scroll to Top